NIH tests Sanofi H7N9 flu vaccine, Novartis/GSK adjuvants
This article was originally published in Scrip
Executive Summary
Studies funded by the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health (NIH), are now underway testing a vaccine candidate from Sanofi Pasteur against the deadly H7N9 flu, which has sickened at least 135 people in China and killed 44, US officials revealed on 18 September.